Home

John Varian

CIK 1416176 · CEO · last filed 2026-01-09

John Varian is a CEO who has filed 68 SEC Form 4 insider transactions across 6 companies since 2008. The most recent filing, for SLS, was dated Jan 9, 2026. Across all open-market trades the lifetime net is −$2.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $998.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$998.7K

Companies

6

Total Filings

68

Lifetime Open-Market Net

-$2.49M

Filer Profile

Reported Address
ARYX THERAPEUTICS,INC.
6300 DUMBARTON CIRCLE
FREMONT, CA 94555
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SLS Director 72,900 $13.70 $998.7K $0 10 2026-01-09
Acorda Therapeutics, Inc. (ACOR) Delisted Director — $0.66 — $0 3 2023-06-23
Zyla Life Sciences (EGLT) Delisted Director — — — $0 1 2018-07-02
Aravive, Inc. (VSAR) Delisted Director 3,713 — — -$20.8K 6 2017-12-22
XOMA Royalty Corp (XOMA) Delisted CEO 5,995 $40.17 $240.8K -$2.47M 41 2017-05-22
ARYx Therapeutics, Inc. (ARYX) Delisted COO & CFO — — — $0 3 2010-03-01

Recent Filings

68 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-09 SLS Grant (A) +50,000 $0 EDGAR
2025-01-14 SLS Grant (A) +12,500 $0 EDGAR
2024-01-25 SLS Grant (A) +6,000 $0 EDGAR
2023-06-23 Acorda Therapeutics, Inc. (ACOR) Delisted Grant (A) — $0 EDGAR
2023-02-03 SLS Grant (A) +2,500 $0 EDGAR
2023-01-04 Acorda Therapeutics, Inc. (ACOR) Delisted Grant (A) — $0 EDGAR
2022-02-01 SLS Grant (A) +1,900 $0 EDGAR
2022-01-04 Acorda Therapeutics, Inc. (ACOR) Delisted Grant (A) — $0 EDGAR
2021-03-08 SLS Grant (A) — $0 EDGAR
2020-03-16 SLS Grant (A) — $0 EDGAR
Showing 1–10 of 68
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.